Francesca Marchetto

Francesca graduated with a Bachelor’s degree in Biotechnology from the University of Trieste and later obtained a Master’s degree in Industrial Biotechnology from the University of Padua. During the early stages of her career, she focused on the application of microalgae for the bioremediation of toxic compounds, such as per- and polyfluoroalkyl substances (PFAS), conducting her research during her studies and fellowship at the University of Padua.

She then pursued a PhD at the Centre of New Technologies (CeNT) at the University of Warsaw, Poland, where she investigated the molecular mechanisms underlying microalgal adaptation to heavy metals. Her work adopted a multidisciplinary approach combining physiological and biochemical analyses with multi-omics techniques—genomics and transcriptomics—and advanced microscopy, including confocal microscopy, scanning electron microscopy with energy-dispersive X-ray spectroscopy (SEM-EDX), serial block-face SEM (SBFSEM), and cryo-electron microscopy (cryo-EM). She was a recipient of the “Initiative of Excellence – Research University” (IDUB) grant at the University of Warsaw.

As Post-doc in the Genomic Laboratory of Dr. Chiara Maria Mazzanti at FPS, she works within the HOPE project (enHanced patient stratificatiOn: exPloring glioblastoma mEchanisms), funded by the Italian Association for Cancer Research (AIRC). Her research is particularly focused on drug repositioning and transcriptome analysis. By employing advanced in silico strategies, she identifies potential anti-cancer compounds through transcriptomic profiling, which are then validated using functional assays within preclinical models.

As Post-doc in the Genomic Laboratory of Dr. Chiara Maria Mazzanti at FPS, she works within the HOPE project (Combining innovative strategies for enHanced patient stratificatiOn: exPloring glioblastoma mEchanisms and new therapies), funded by the Italian Association for Cancer Research (AIRC). Her research is particularly focused on translational medicine based on static and dynamic precision medicine. Within the Hope project she will be mainly involved in drug repositioning and transcriptome analysis. By employing advanced in silico strategies, we will identify potential anti-cancer compounds through transcriptomic profiling, which are then validated using functional assays within preclinical models.